Premium
Allogeneic graft‐versus‐hepatoblastoma effect
Author(s) -
Inaba Hiroto,
Handgretinger Rupert,
Furman Wayne,
Hale Gregory,
Leung Wing
Publication year - 2006
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20404
Subject(s) - hepatoblastoma , medicine , hematopoietic stem cell transplantation , blood cancer , chemotherapy , oncology , disease , refractory (planetary science) , transplantation , graft versus host disease , haematopoiesis , gastroenterology , surgery , stem cell , cancer , physics , astrobiology , biology , genetics
Although the survival rate for pediatric patients with hepatoblastoma has improved, prognosis is still poor when the disease is unresectable and refractory to chemotherapy. Therefore, novel approaches are warranted. Herein, we describe a patient with recurrent metastatic hepatoblastoma who received a nonmyeloablative hematopoietic stem cell transplantation from an HLA‐matched unrelated donor. After withdrawal of immunosuppressant and establishment of full donor T‐cell engraftment, the tumor regressed and serum α‐fetoprotein level decreased in concurrence with the onset of graft‐versus‐host disease (GVHD). Her disease recurred when GVHD resolved. This patient's clinical course provides evidence for the probable existence of allogeneic graft‐versus‐hepatoblastoma effect. Pediatr Blood Cancer 2006, 46:501–505. © 2005 Wiley‐Liss, Inc.